Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data CRISPR Therapeutics AG files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
5.16
41
3.12
290
0.72
915
1.2
371
37.3
3.51
Research and development
42.2
69.8
114
179
221
341
462
387
310
285
General and administrative
31.1
35.8
48.3
63.5
85.7
99.7
102
76.2
73
73.5
Operating expenses
73.3
106
162
243
355
541
674
594
504
668
Operating income
-68.1
-64.6
-159
46.7
-354
374
-673
-223
-467
-665
Interest income
23.3
76.4
104
Other non-operating income
45.4
-1.96
-5.49
20.6
6.38
6
22.7
71.8
104
86.6
Pre-tax income
-22.7
-66.6
-164
67.3
-348
380
-651
-151
-363
-578
Income tax
0.48
1.75
0.55
0.45
0.81
1.87
-0.33
2.89
3.59
3.63
Net income to minority interests
-0.03
Net income
-23.2
-68.4
-165
66.9
-349
378
-650
-154
-366
-582
EBITDA
-67.2
-61.6
-155
51.5
-345
391
-649
-203
-447
-645
EPS, basic
-1.89
-1.71
-3.44
1.23
-5.29
4.97
-8.36
-1.94
-4.34
-6.47
EPS, diluted
-1.89
-1.71
-3.44
1.17
-5.29
4.70
-8.36
-1.94
-4.34
-6.47
Shares, basic (weighted)
12.3
40.1
48
54.4
65.9
75.9
77.7
79.2
84.4
89.9
Shares, diluted (weighted)
12.3
40.1
48
56.9
65.9
80.4
77.7
79.2
84.4
89.9
Balance sheet
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
316
240
457
944
1,169
923
212
389
298
348
Short-term investments
0
522
1,456
1,603
1,304
1,606
1,628
Receivables
3.16
2.63
0.09
0.1
0.14
0.31
0
200
25
0
Other current assets
1.51
6
9.66
43.7
26.1
38.1
37.7
14.4
8.31
9.84
Total current assets
320
248
466
988
1,717
2,418
1,853
1,908
1,937
1,986
Property, plant and equipment
21
18.9
18.5
31.3
42.2
138
164
152
134
116
Lease right-of-use assets
41.5
50.9
174
157
154
143
132
Intangible assets
0.4
0.34
0.29
0.24
0.18
0.13
0.07
0.02
0
Long-term investments
0
53.1
1.97
0
0
Other non-current assets
0.2
0.61
0.67
1.1
1.29
5.29
4.64
1.98
15.8
24.4
Total assets
345
271
489
1,067
1,828
2,752
2,243
2,230
2,242
2,265
Accounts payable
4.57
1.64
5.07
5.94
9.09
14.8
27.4
38.1
14.7
11.1
Accrued liabilities
16.3
11.4
20.9
30.2
53.8
91
77.7
45.3
41.1
89.4
Deferred revenue
0.1
0.96
2.34
1.01
0
4.11
3.85
15.8
Total current liabilities
22
14.5
27.7
57.1
94.3
120
121
109
87.8
149
Lease liabilities
44.1
50.1
213
228
223
206
188
Other non-current liabilities
0.19
0.31
0.24
14.4
7.63
7.34
5.97
0.96
3.44
6.14
Total liabilities
112
83.5
96.8
127
164
352
368
347
310
343
Total debt
0
Paid-in capital
289
312
682
1,162
2,236
2,598
2,735
2,878
3,294
3,862
Retained earnings
-57.1
-125
-292
-225
-574
-196
-846
-1,000
-1,366
-1,948
Treasury stock
0
0
-0.06
-0.06
-0.06
-0.06
-0.06
-0.06
-0.06
-0.06
Other comprehensive income
-0.03
0.01
-0.01
0.01
-0.08
-5.07
-15.6
1.91
1.84
4.82
Shareholders' equity
233
188
392
939
1,664
2,399
1,875
1,883
1,932
1,922
Total equity
233
188
392
939
1,664
2,399
1,875
1,883
1,932
1,922
Total liabilities and equity
345
271
489
1,067
1,828
2,752
2,243
2,230
2,242
2,265
Shares outstanding
39.7
40.6
51.9
60.8
73.9
77
78.5
80
85.7
95.9
Cash flow statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-23.2
-68.4
-165
66.9
-349
378
-650
-154
-366
-582
Depreciation and amortization
0.93
3.02
3.52
4.73
9.18
18
24.2
19.8
19.3
19.5
Stock-based compensation
10.8
18.9
35
44.1
66
102
97.9
81
86.6
72.5
Deferred income tax
-0.14
0.18
0.01
-0.03
0.41
1.75
-1.01
-0.42
-0.48
0.92
Change in receivables
-2.82
0.53
2.54
-0.01
-0.05
-0.16
0.31
-200
175
25
Change in payables
3.86
-0.83
12.1
5.03
25.7
37.5
5.16
-20.2
-27.3
44.9
Cash from operations
-52.9
-70.1
-96.2
56.7
-238
539
-496
-260
-143
-345
Capital expenditures
-3.02
-7.81
-2.77
-6.68
-18.4
-81.7
-37.2
-9.47
-1.9
-0.91
Purchases of investments
-0.5
-594
-1,509
-1,418
-1,066
-1,463
-1,008
Sales and maturities of investments
71.2
556
1,196
1,453
1,208
1,011
Cash from investing
31.9
-8.31
-2.77
1.33
-541
-1,035
-259
375
-280
-31.8
Stock issued
89.1
0
307
415
982
213
0.97
32.7
301
398
Share buybacks
-0.06
Cash from financing
183
2.61
316
431
1,016
251
38.6
62.7
332
426
Net change in cash
162
-75.8
217
489
237
-246
-716
177
-91.3
49.3
Free cash flow
-55.9
-77.9
-99
50
-257
457
-533
-270
-145
-346
Income taxes paid
2.99
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $54.23 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Operating margin
-3,990.0%
Operating income / revenue.
EBITDA margin
-3,851.0%
EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin
-3,346.0%
Pre-tax income / revenue.
Net margin
-3,369.0%
Net income / revenue.
FCF margin
-2,773.0%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-2,760.0%
Cash from operations / revenue.
Return on equity (ROE)
-25.8%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-17.0%
Net income / average total assets.
Return on invested capital (ROIC)
-20.7%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
R&D / revenue
2,077.0%
Research and development expense / revenue.
Stock-based pay / revenue
510.2%
Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue
13.0%
Capital expenditures / revenue.
D&A / revenue
139.5%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
-90.6%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
43.1%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
37.3%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Book value growth, 1y
-0.5%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
0.8%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
2.9%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
1.0%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
0.3%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
4.4%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
6.6%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
5.0%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
6.4%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
17.8x
Current assets / current liabilities.
Quick ratio
17.8x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
17.8x
(Cash + short-term investments) / current liabilities.
Debt / equity
0.34x
Total debt / shareholders' equity. Not shown when equity is negative.
Debt / assets
22.1%
Total debt / total assets.
Liabilities / assets
34.1%
Total liabilities / total assets.
Net debt
-$1.78B
Total debt - cash - short-term investments. Negative means more cash than debt.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$0.14
Revenue / diluted weighted shares.
FCF per share
-$3.85
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$3.83
Cash from operations / diluted weighted shares.
Book value per share
$18.07
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
392x
Market cap / revenue.
P/B
3.00x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
3.00x
Market cap / tangible book value, when positive.
EV/Sales
259x
Enterprise value / revenue.
FCF yield
-7.1%
Free cash flow / market cap.
Earnings yield
-8.6%
Net income / market cap (the inverse of P/E).
What was CRISPR Therapeutics AG's revenue in fiscal 2025?
CRISPR Therapeutics AG reported revenue of $3.5M for fiscal 2025, 90.6% lower than the year before.
Was CRISPR Therapeutics AG profitable in fiscal 2025?
No. It reported a net loss of $581.6M.
How much free cash flow did CRISPR Therapeutics AG generate in fiscal 2025?
Cash from operations of $345.0M minus capital expenditures of $914.0K left free cash flow of -$345.9M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.